"An investment in knowledge pays the best interest."

DESIGN OF THEROZAP WORKING PROTOTYPE AND SIGNS SERVICE AGREEMENT WITH UNIVERSITY HEATH NETWORK TO INITIATE TESTING AGAINST THE ZIKA AND WEST NILE VIRUSES

 

The design of the working prototype for The Jenex Corp.'s (JEN.H -V) patent-pending TherOZap is now complete. Images of the working prototype can be viewed on the TherOZap website.

Jenex has optimized the features on the TherOZap working prototype device to determine its effectiveness at inactivating both the Zika virus and West Nile virus and potentially other mosquito borne diseases. Further, Jenex would like to report that it has signed an agreement with University Health Network ("UHN") to initiate testing of the TherOZap device. Over the next several weeks Jenex will be coordinating with the Techna Institute at UHN to devise the protocols for the initial tests. It is anticipated that once all testing is complete Jenex will finalize the features for the consumer product device and seek regulatory approval where required.

Rob Fia, CEO commented:

"We are very excited to finalize the TherOZap working prototype. Jenex looks forward to working with UHN to begin the initial testing to determine the effectiveness of the device at inactivating both the Zika and West Nile viruses. Jenex is considering some unique applications for the tests that may become part of the final consumer product. We will have more to report on these unique applications in the near future."

Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997. Jenex continues to further develop, and explore other applications, for its platform technology.

About Jenex:

Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (NEX: JEN.H). For more information visit: www.thejenexcorporation.com or www.therozap.com